These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 23837139)

  • 21. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
    Bruno S; Shiffman ML; Roberts SK; Gane EJ; Messinger D; Hadziyannis SJ; Marcellin P
    Hepatology; 2010 Feb; 51(2):388-97. PubMed ID: 19918980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
    Kim JI; Kim SH; Lee BS; Lee HY; Lee TH; Kang YW; Lee HIe; Kim AN; Nam SW; Park BC; Chae HB; Kim SB; Song IH; Park JY; Kim HS
    Korean J Hepatol; 2008 Dec; 14(4):493-502. PubMed ID: 19119244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].
    Kim KT; Han SY; Kim JH; Yoon HA; Baek YH; Kim MJ; Lee SW; Jang JS; Lee JH; Roh MH
    Korean J Hepatol; 2008 Mar; 14(1):36-45. PubMed ID: 18367856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
    Missiha S; Heathcote J; Arenovich T; Khan K;
    Am J Gastroenterol; 2007 Oct; 102(10):2181-8. PubMed ID: 17640318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
    Bruno S; Stroffolini T; Colombo M; Bollani S; Benvegnù L; Mazzella G; Ascione A; Santantonio T; Piccinino F; Andreone P; Mangia A; Gaeta GB; Persico M; Fagiuoli S; Almasio PL;
    Hepatology; 2007 Mar; 45(3):579-87. PubMed ID: 17326216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
    Helbling B; Jochum W; Stamenic I; Knöpfli M; Cerny A; Borovicka J; Gonvers JJ; Wilhelmi M; Dinges S; Müllhaupt B; Esteban A; Meyer-Wyss B; Renner EL;
    J Viral Hepat; 2006 Nov; 13(11):762-9. PubMed ID: 17052276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
    Perz JF; Armstrong GL; Farrington LA; Hutin YJ; Bell BP
    J Hepatol; 2006 Oct; 45(4):529-38. PubMed ID: 16879891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global epidemiology of hepatitis C virus infection.
    Shepard CW; Finelli L; Alter MJ
    Lancet Infect Dis; 2005 Sep; 5(9):558-67. PubMed ID: 16122679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
    Marrache F; Consigny Y; Ripault MP; Cazals-Hatem D; Martinot M; Boyer N; Degott C; Valla D; Marcellin P
    J Viral Hepat; 2005 Jul; 12(4):421-8. PubMed ID: 15985014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in treatment outcome for hepatitis C among ethnic groups.
    Hepburn MJ; Hepburn LM; Cantu NS; Lapeer MG; Lawitz EJ
    Am J Med; 2004 Aug; 117(3):163-8. PubMed ID: 15276594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, management, and treatment of hepatitis C.
    Strader DB; Wright T; Thomas DL; Seeff LB;
    Hepatology; 2004 Apr; 39(4):1147-71. PubMed ID: 15057920
    [No Abstract]   [Full Text] [Related]  

  • 35. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of chronic viral hepatitis: a need for reassessment.
    Scheuer PJ
    J Hepatol; 1991 Nov; 13(3):372-4. PubMed ID: 1808228
    [No Abstract]   [Full Text] [Related]  

  • 37. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
    Lee HS; Kweon YO; Tak WY; Park SY; Kang EJ; Lee YL; Yang HM; Park HW
    Clin Mol Hepatol; 2013 Jun; 19(2):148-55. PubMed ID: 23837139
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.